1. Scrip
  2. >>Business
  3. >>Financing

IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September

 
• By Mandy Jackson

There were only two biopharma IPOs in the US during August, bringing the year's total to 47. But with eight new filings in August, launches in September could rival July's total of nine first-time offerings, especially since this average return on this year's IPOs remains in positive territory.

stock

Biopharmaceutical companies launched only two initial public offerings in the US during August, but eight more drug developers entered the queue, setting up September to be another busy IPO month, rivaling July's nine offerings and June's 14.

Twenty-six of the 47 biopharma firms that went public in the first eight months of 2018 were trading in positive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.

Finance Watch: Braveheart Launches With $185m To Start Late-Stage Trials

 
• By Mandy Jackson

Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).

More from Business

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.

Finance Watch: Public Biopharma Company Financings Surged Globally In Q3

 
• By Mandy Jackson

Public Company Financings: Biomedtracker’s third quarter report shows a big jump from Q2 in follow-on offerings, private placements and debt. Also, Evommune brings the US biopharma IPO tally for 2025 to a dozen and Merck’s Blackstone deal gives it $700m to develop a key ADC asset.